Skip to main content Skip to main navigation menu Skip to site footer
MedNext Journal of Medical and Health Sciences
Review
DOI: 10.54448/mdnt22107
Submitted: 22-02-2022
Published: 22-02-2022

Use of ivermectin in the treatment of COVID-19: a review

UNORP - University Center North Paulista - Sao Jose do Rio Preto, Sao Paulo, Brazil / UNIPOS - Post graduate and continuing education, Sao Jose do Rio Preto, Sao Paulo, Brazil
UNORP - University Center North Paulista - Sao Jose do Rio Preto, Sao Paulo, Brazil / UNIPOS - Post graduate and continuing education, Sao Jose do Rio Preto, Sao Paulo, Brazil
UNORP - University Center North Paulista - Sao Jose do Rio Preto, Sao Paulo, Brazil / UNIPOS - Post graduate and continuing education, Sao Jose do Rio Preto, Sao Paulo, Brazil
COVID-19 SARS-CoV-2 Ivermectin Treatment Prevention

Abstract

Introduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2.

Metrics

Metrics Loading ...

References

  1. Ferreira LLG, Andricopulo AD. Medicamentos e tratamentos para a Covid-19. Rev. Estudos Avançados, v. 34, n. 100, p.7-27, 2020. Disponível em: < https://www.scielo.br/pdf/ea/v34n100/1806-9592-ea-34-100-7.pdf> Acesso em: 05 mar. 2021.
  2. Marra LP. Ivermectina para Covid-19. Revisão sistemática rápida. 24 f., 2020. Disponível em: < https://docs.bvsalud.org/biblioref/2020/06/1099488/rs_rapida_ivermectina_covid19_06_05_20-1.pdf> Acesso em: 05 mar. 2021.
  3. Person OC. et al. Intervenção com ivermectina para COVID-19 (SARS-Cov 2): sinopse baseada em evidências. 2021. 20f. Dissertação (Doutorado em Saúde) – UNIFESP, 2021. Disponível em: < https://preprints.scielo.org/index.php/scielo/preprint/view/1871> Acesso em: 05 mar. 2021.
  4. Floriani ID. et al. Exposição de pacientes da emergência pediátrica a exames de imagem, na atualidade e em tempos de covid-19: uma revisão integrativa. Rev. Paul. Pediatr., v. 40, 2020. Disponível em: < https://www.scielo.br/pdf/rpp/v40/pt_1984-0462-rpp-40-e2020302.pdf> Acesso em: 05 mar. 2021.
  5. Heidary F, Gharebaghi R. Ivermectina: uma revisão sistemática dos efeitos antivirais do regime complementar de COVID-19. Rev. The Journal of Antibiotics, v. 73, p. 593-602, 2020. Disponível em: < https://doi.org/10.1038/s41429-020-0336-z> Acesso em: 05 mar. 2021.
  6. Kircik LHMD. et al. Mais de 25 anos de experiência clínica com ivermectina: uma visão geral da segurança para um número crescente de indicações. Rev. J Drugs Dermatol, v. 15, ed. 3, mar. 2016. Disponível em: <https://jddonline.com/articles/dermatology/S1545961616P0325X> Acesso em: 10 mar. 2021.
  7. Pandey S. et al. Ivermectin in COVID-19: What do we know? Diabetes Metab. Syndr., v. 14, n. 6, p. 1921-1922, nov.-dez. 2020. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521351/> Acesso em: 30 mar. 2021.
  8. Hellwing MD, Maia A. Uma profilaxia COVID-19? Menor incidência associada à administração profilática de ivermectina. Int. J. Antimicrob Agents, v. 57, n. 1, 2021. Disponível em: < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698683/> Acesso em: 30 mar. 2021.
  9. Caly L. et al The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res., v. 178, jun. 2020. Disponível em: < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/> Acesso em: 30 mar. 2021.
  10. Schmith VD, Zhou, J.; Lohmer, L. R. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19. Clinical Pharmacology e Therapeutics, v. 108, n. 4, p. 762-765, out. 2020. Disponível em: < https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1889> Acesso em: 31 mar. 2021.
  11. Rajter JC. et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019. Elsevier Public Heath Emergency Collection, v. 159, n. 1, p. 85-92, jan. 2021. Disponível em: < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/> Acesso em: 30 mar. 2021.
  12. Ahmed S. et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis, v. 103, p. 214-216, 2021. Disponível em: < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709596/> Acesso em: 31 mar. 2021.

How to Cite

Zanoti, E. B., Porto, R. M., & Scriboni, A. B. (2022). Use of ivermectin in the treatment of COVID-19: a review. MedNEXT Journal of Medical and Health Sciences, 3(1). https://doi.org/10.54448/mdnt22107